Uveitis is a disease involving the eye, affecting the iris, ciliary body, retina and their associated blood vessels, among others. The non-infectious type of uveitis is linked to immune-related factors and its pathogenesis remains poorly understood.
To date, therapies for multiple sclerosis (MS) focus on modifying or suppressing the immune system rather than on remyelination. Recent findings have pointed to the κ-opioid receptor (KOR) as a therapeutic target for remyelination, but several KOR agonists have undesired side effects that limit their use. Researchers from the Victoria University of Wellington have tested KOR agonists derived from U-50488 in the preclinical setting for the management of MS.
The FDA has awarded U.S. orphan drug designation to Eydisbio Inc.’s EYD-001 (formerly HS-276), a highly selective and potent, orally bioavailable TAK1 inhibitor for the treatment of systemic sclerosis. Eydisbio plans to initiate clinical trials in the near future.
Researchers from Moderna Inc. and affiliated organizations presented preclinical data for the novel mRNA-lipid nanoparticle (LNP) vaccine, mRNA-1769, against mpox virus.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented indazole compounds acting as membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Chong Kun Dang Pharmaceutical Corp. has disclosed 1,3,4-oxadiazole-containing compounds acting as histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of prion diseases, asthma, psoriasis, inflammatory bowel disease, autosomal dominant polycystic kidney, stroke, Charcot-Marie-Tooth disease and uveitis, among others.
Reglagene Inc. has prepared and tested compounds reported to be useful for the treatment of cancer, familial Mediterranean fever, gout and nail fungal infection.
RSS
